ES2785094T3 - Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados - Google Patents

Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados Download PDF

Info

Publication number
ES2785094T3
ES2785094T3 ES12850971T ES12850971T ES2785094T3 ES 2785094 T3 ES2785094 T3 ES 2785094T3 ES 12850971 T ES12850971 T ES 12850971T ES 12850971 T ES12850971 T ES 12850971T ES 2785094 T3 ES2785094 T3 ES 2785094T3
Authority
ES
Spain
Prior art keywords
glutamine
salt
diabetes
use according
person
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12850971T
Other languages
English (en)
Spanish (es)
Inventor
Yutaka Niihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emmaus Medical Inc
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48470183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2785094(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Application granted granted Critical
Publication of ES2785094T3 publication Critical patent/ES2785094T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ES12850971T 2011-11-21 2012-11-17 Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados Active ES2785094T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161629633P 2011-11-21 2011-11-21
PCT/US2012/000557 WO2013077893A1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Publications (1)

Publication Number Publication Date
ES2785094T3 true ES2785094T3 (es) 2020-10-05

Family

ID=48470183

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12850971T Active ES2785094T3 (es) 2011-11-21 2012-11-17 Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados

Country Status (10)

Country Link
US (2) US20130143968A1 (enExample)
EP (2) EP2782588B1 (enExample)
JP (4) JP6089042B2 (enExample)
CN (3) CN103945858A (enExample)
BR (1) BR112014011898A2 (enExample)
ES (1) ES2785094T3 (enExample)
HK (1) HK1257401A1 (enExample)
IN (1) IN2014KN01037A (enExample)
PH (2) PH12020550726B1 (enExample)
WO (1) WO2013077893A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2003072556A1 (en) * 2001-06-27 2003-09-04 Prosidion Ltd. Glutaminyl based dpiv inhibitors
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CA2774197A1 (en) * 2006-04-22 2008-04-03 Harbor Biosciences, Inc. Drugs and uses to modulate inflammation, metabolic disorders and other conditions
WO2008038771A1 (en) * 2006-09-29 2008-04-03 Ajinomoto Co., Inc. Glutamine-containing composition for increasing blood flow
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
HUE034551T2 (en) * 2009-01-12 2018-02-28 Biokier Inc Composition and method for treatment of diabetes
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
MX2012003459A (es) * 2009-09-23 2012-05-22 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.

Also Published As

Publication number Publication date
CN103945858A (zh) 2014-07-23
HK1257401A1 (zh) 2019-10-18
EP2782588A1 (en) 2014-10-01
JP6389495B2 (ja) 2018-09-12
BR112014011898A2 (pt) 2017-05-16
JP2014533689A (ja) 2014-12-15
JP6089042B2 (ja) 2017-03-01
PH12020550726A1 (en) 2021-06-14
US20190192463A1 (en) 2019-06-27
EP3437649A1 (en) 2019-02-06
PH12014501052B1 (en) 2020-10-09
PH12014501052A1 (en) 2014-06-30
JP2018199692A (ja) 2018-12-20
JP6550160B2 (ja) 2019-07-24
CN108354916A (zh) 2018-08-03
EP2782588A4 (en) 2015-05-20
PH12020550726B1 (en) 2022-11-09
US20130143968A1 (en) 2013-06-06
IN2014KN01037A (enExample) 2015-10-09
CN108478551A (zh) 2018-09-04
JP2018115175A (ja) 2018-07-26
JP2017052766A (ja) 2017-03-16
EP2782588B1 (en) 2020-04-15
WO2013077893A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
US11141399B2 (en) Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
ES2959111T3 (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de Nrf2
ES2820025T3 (es) Uso de derivados 2-hidroxilados de ácidos grasos poliinsaturados como medicamentos
US11224585B2 (en) Compositions containing omega-3 oil and uses thereof
JP7514457B2 (ja) 片頭痛の予防および治療
CN103285394B (zh) 使用硝化脂质治疗脂质病症和肥胖以及与脂质和肥胖相关的病状
ES2585066T3 (es) Composiciones para el tratamiento de trastornos neurológicos
US20180085334A1 (en) Methods of treating pediatric metabolic syndrome
US20140186438A1 (en) Compositions comprising epa and obeticholic acid and methods of use thereof
JP2017519028A (ja) 重度の高トリグリセリド血症の処置
US20190192463A1 (en) Methods and compositions for the treatment of diabetes and related systems
JP5063369B2 (ja) メグリチニド類を含有する肝臓線維化予防用医薬組成物
WO2021150958A1 (en) Treatment methods using a combination of pantethine and a vanin agonist
US20240382445A1 (en) Methods of adjuvant therapy
WO2023100938A1 (ja) 酸化ストレス緩和方法
HK1216847A1 (zh) 用於产生升高和持久的酮症的组合物和方法